We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| NKGen Biotech Inc | NASDAQ:NKGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.37 | 1.37 | 1.46 | 1.50 | 1.36 | 1.37 | 122,333 | 00:47:52 |
From Jun 2023 to Jun 2024
By Chris Wack
NKGen Biotech shares were up 8% to $3.25 after the company said the U.S. Food and Drug Administration has cleared its investigational new drug application for SNK01 natural killer cell therapy for treatment of moderate Alzheimer's disease.
The stock hit its 52-week low of $2.86 on Oct. 13, and is down 67% in the past 12 months.
SNK01 is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression.
The company said this approved trial of 30 patients with moderate Alzheimer's will hopefully begin before the end of this year, and the first interim data is expected in early third quarter of 2024.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 24, 2023 10:41 ET (14:41 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year NKGen Biotech Chart |
1 Month NKGen Biotech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
